NVIDIA & Eli Lilly launch $1 billion AI Lab to reinvent drug discovery

Jubilant Biosys doubles early chemistry scale-up capacity with Noida facility

The multimillion-dollar facility combines discovery and early-phase scale-up capabilities with R&D labs and two pilot plants

Novartis to open Florida radioligand facility

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism

Prokaryotics and Basilea team up to tackle deadly fungal infections

The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections

Nimbus Therapeutics and Eli Lilly team up on novel obesity therapy

The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases

Oculis’ Privosegtor wins FDA breakthrough therapy status for Optic Neuritis

The FDA designation follows visual-function results from the Phase 2 ACUITY trial

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation

Ascletis Pharma gets FDA nod for Phase II diabetes trial of oral GLP-1 drug

The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety